Management of severe acne

British Journal of Dermatology

Volumn 172, Issue S1, 2015, Pages 27-36

  Zouboulis, C C ^a   Bettoli, V ^b  

^a DESSAU MEDICAL CENTER   (Germany)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIBIOTIC AGENT; CORTICOSTEROID; ISOTRETINOIN; ANTIINFECTIVE AGENT; DERMATOLOGICAL AGENT; TERATOGENIC AGENT;

ACNE; ACNE FULMINANS; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; CHEILITIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DARK ADAPTATION; DEPRESSION; DISEASE SEVERITY; EVIDENCE BASED PRACTICE; EYE DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SEBUM SECRETION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC THERAPY; TERATOGENICITY; ULCERATIVE COLITIS; VISUAL DISORDER; XEROSIS; ACNE VULGARIS; ADOLESCENT; ADULT; CHRONIC DISEASE; FEMALE; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PSYCHOLOGY; SCAR;

ACNE VULGARIS; ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANDROGEN ANTAGONISTS; ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CICATRIX; DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; MALE; PRACTICE GUIDELINES AS TOPIC; TERATOGENS;

EID: 84931863320     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13639     Document Type: Review

References (90)

1. Zouboulis CC,. Acne: current aspects on pathology and treatment. Experimental Dermatol 1999; 1: 6-37.
2. Gollnick H, Zouboulis CC,. Not all acne is acne vulgaris. Dtsch Arztbl Int 2014; 111: 301-12.
3. Ghodsi SZ, Orawa H, Zouboulis CC,. Prevalence, severity and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol 2009; 129: 2136-41.
4. Bhate K, Williams HC,. Epidemiology of acne vulgaris. Br J Dermatol 2013; 168: 474-85.
5. Silverberg JI, Silverberg NB,. Epidemiology and extracutaneous comorbidities of severe acne in adolescence: a U.S. population-based study. Br J Dermatol 2014; 170: 1136-42.
6. Navarini AA, Simpson MA, Weale M, et al,. Genome-wide association study identifies three novel susceptibility loci for severe acne vulgaris. Nat Commun 2014; 5: 4020.
7. He L, Wu WJ, Yang JK, et al,. Two new susceptibility loci 1q24.2 and 11p11.2 confer risk to severe acne. Nat Commun 2014; 5: 2870.
8. Zhang M, Qureshi AA, Hunter DJ, Han J,. A genome-wide association study of severe teenage acne in European Americans. Hum Genet 2014; 133: 259-64.
9. Chalmers RL,. The evidence for the role of transforming growth factor-beta in the formation of abnormal scarring. Int Wound J 2011; 8: 218-23.
10. Lucky AW, Biro FM, Huster GA, et al,. Acne vulgaris in early adolescent boys: correlations with pubertal maturation and age. Arch Dermatol 1991; 127: 210-16.
11. Lucky AW, Biro FM, Simbart LA, et al,. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Pediatr 1997; 130: 30-9.
12. Zouboulis CC,. Acne as a chronic systemic disease. Clin Dermatol 2014; 32: 389-96.
13. Chen W, Obermayer-Pietsch B, Hong J-B, et al,. Acne-associated syndromes: models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol 2011; 25: 637-46.
14. Witchel SF, Recabarren SE, González F, et al,. Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine 2012; 42: 526-34.
15. Zouboulis CC, Piquero-Martin J,. Update and future of systemic acne treatment. Dermatology 2003; 206: 37-53.
16. Zouboulis CC,. Acne and sebaceous gland function. Clin Dermatol 2004; 22: 360-6.
17. Nast A, Dréno B, Bettoli V, et al,. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012; 26 (Suppl. 1): 1-29.
18. Karvonen SJ,. Acne fulminans. Report of clinical findings and treatment of twenty-four patients. J Am Acad Dermatol 1993; 28: 572-9.
19. Seukeran DC, Cunliffe WJ,. The treatment of acne fulminans: A review of 25 cases. Br J Dermatol 1999; 141: 307-9.
20. Bass D, Zouboulis CC,. Treatment of acne fulminans with isotretinoin and prednisolone. Z Hautkr 2001; 76: 473 (in German).
21. Simonart T, Dramaix M, de Maertelaer V,. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol 2008; 158: 208-16.
22. Ochsendorf F,. [Systemic antibiotic therapy of acne vulgaris ]. J Dtsch Dermatol Ges 2010; 8 (Suppl. 1): S31-46 (in German).
23. Smith K, Leyden JJ,. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005; 27: 1329-42.
24. Layton AM, Cunliffe WJ,. Phototoxic eruptions due to doxycycline-a dose-related phenomenon. Clin Exp Dermatol 1993; 18: 425-7.
25. Lim DS, Murphy GM,. High-level ultraviolet A photoprotection is needed to prevent doxycycline phototoxicity: lessons learned in East Timor. Br J Dermatol 2003; 149: 213-14.
26. Ochsendorf F,. Minocycline in acne vulgaris: benefits and risks. Am J Clin Dermatol 2010; 11: 327-41.
27. Bjellerup M, Ljunggren B,. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema. Br J Dermatol 1994; 130: 356-60.
28. Katsambas A, Towarky AA, Stratigos J,. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987; 116: 387-91.
29. Archer JS, Archer DF,. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002; 46: 917-23.
30. Sieber MA, Hegel JK,. Azelaic acid: properties and mode of action. Skin Pharmacol Physiol 2014; 27 (Suppl. 1): 9-17.
31. Gollnick HP, Graupe K, Zaumseil RP,. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne. Eur J Dermatol 2001; 11: 538-44.
32. Gollnick H, Albring M, Brill K,. [The effectiveness of oral cyproterone acetate in combination with ethinylestradiol in acne tarda of the facial type]. Ann Endocrinol (Paris) 1999; 60: 157-66 (in French).
33. Zouboulis CC, Rabe T,. [Hormonal antiandrogens in acne therapy]. J Dtsch Dermatol Ges 2010; 8 (Suppl. 1): S60-74 (in German).
34. Fritsch M, Orfanos CE, Zouboulis CC,. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 2001; 116: 793-800.
35. Seiffert K, Seltmann H, Fritsch M, Zouboulis CC,. Inhibition of 5α-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro. Horm Metab Res 2007; 39: 141-8.
36. Raudrant D, Rabe T,. Progestogens with antiandrogenic properties. Drugs 2003; 63: 463-92.
37. Worret I, Arp W, Zahradnik HP, et al,. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 2001; 203: 38-44.
38. Orfanos CE, Zouboulis CC,. Oral retinoids in the treatment of seborrhoea and acne. Dermatology 1998; 196: 140-7.
39. Layton AM, Knaggs H, Taylor J, Cunliffe WJ,. Isotretinoin for acne vulgaris -10 years later: a safe and successful treatment. Br J Dermatol 1993; 129: 292-6.
40. Ganceviciene R, Zouboulis CC,. Isotretinoin: state of the art treatment for acne vulgaris. Expert Rev Dermatol 2007; 2: 693-706.
41. Leyden JJ, McGinley KJ, Foglia AN,. Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. J Invest Dermatol 1986; 86: 390-3.
42. Peck GL, Olsen TG, Butkus D, et al,. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6: 735-45.
43. Strauss JS, Leyden JJ, Lucky AW, et al,. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol 2001; 45: 187-95.
44. Strauss JS, Rapini RP, Shalita AR, et al,. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10: 490-6.
45. Jones DH, King K, Miller AJ, Cunliffe WJ,. A dose-response study of 13-cis-retinoic acid in acne vulgaris. Br J Dermatol 1983; 108: 333-43.
46. King K, Jones DH, Daltrey DC, Cunliffe WJ,. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol 1982; 107: 583-90.
47. van der Meeren HL, van der Schroeff JG, Stijnen T, et al,. Dose-response relationship in isotretinoin therapy for conglobate acne. Dermatologica 1983; 167: 299-303.
48. Al Mishari MA,. A study of isotretinoin (Roaccutan) in nodulocystic acne. Clin Trials J 1986; 23: 1-5.
49. Pigatto PD, Finzi AF, Altomare GF, et al,. Isotretinoin versus minocycline in cystic acne: a study of lipid metabolism. Dermatologica 1986; 172: 154-9.
50. Lester RS, Schachter GD, Light MJ,. Isotretinoin and tetracycline in the management of severe nodulocystic acne. Int J Dermatol 1985; 24: 252-7.
51. Tan J, Humphrey S, Vender RA, et al,. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol 2014; 171: 1508-16.
52. Dhir R, Gehi NP, Agarwal R, More YE,. Oral isotretinoin is as effective as a combination of oral isotretinoin and topical anti-acne agents in nodulocystic acne. Indian J Dermatol Venereol Leprol 2008; 74: 187.
53. Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ,. Isotretinoin for the treatment of acne vulgaris: which factors may predict the need for more than one course? Br J Dermatol 1993; 129: 297-301.
54. Chivot M, Midoun H,. Isotretinoin and acne: a study of relapses. Dermatologica 1990; 180: 240-3.
55. Zouboulis CC,. The truth behind this undeniable efficacy-recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 2006; 212: 99-100.
56. European Medicines Agency-Committee for Proprietary Medicinal Products. European Directive for Systemic Isotretinoin Prescription. London: European Medicines Agency, 2003.
57. Layton AM, Dreno B, Gollnick HPM, Zouboulis CC,. A review of the European directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol 2006; 20: 773-6.
58. Maloney ME, Stone SP,. Isotretinoin and iPledge: a view of results. J Am Acad Dermatol 2011; 65: 418-19.
59. Wolverton SE, Harper JC,. Important controversies associated with isotretinoin therapy for acne. Am J Clin Dermatol 2013; 14: 71-6.
60. Marqueling AL, Zane LT,. Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 2007; 26: 210-20.
61. Sundström A, Alfredsson L, Sjölin-Forsberg G, et al,. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. BMJ 2010; 341: c5812.
62. Alhusayen RO, Juurlink DN, Mamdani MM, et al,. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study. J Invest Dermatol 2013; 133: 907-12.
63. Etminan M, Bird ST, Delaney JA, et al,. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol 2013; 149: 216-20.
64. Racine A, Cuerq A, Bijon A, et al,. Isotretinoin and risk of inflammatory bowel disease: a French nationwide study. Am J Gastroenterol 2014; 109: 563-9.
65. Fraunfelder FT, Fraunfelder FW, Edwards R,. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol 2001; 132: 299-305.
66. Hartung B, Merk HF, Huckenbeck W, et al,. Severe generalised rhabdomyolysis with fatal outcome associated with isotretinoin. Int J Legal Med 2012; 126: 953-6.
67. Taylor PW, Keenan MH,. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane. Curr Med Res Opin 2006; 22: 603-15.
68. Lagan BM, Dolk H, White B, et al,. Assessing the availability of the teratogenic drug isotretinoin outside the pregnancy prevention programme: a survey of e-pharmacies. Pharmacoepidemiol Drug Saf 2014; 23: 411-18.
69. Mandekou-Lefaki I, Delli F, Teknetzis A, et al,. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res 2003; 23: 41-6.
70. Borghi A, Mantovani L, Minghetti S, et al,. Low-cumulative dose isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission. J Eur Acad Dermatol Venereol 2011; 25: 1094-8.
71. Webster GF, Leyden JJ, Gross JA,. Comparative pharmacokinetic profiles of a novel isotretinoin formulation (isotretinoin-Lidose) and the innovator isotretinoin formulation: a randomized, 4-treatment, crossover study. J Am Acad Dermatol 2013; 69: 762-7.
72. Webster GF, Leyden JJ, Gross JA,. Results of a phase III, double-blind, randomized, parallel-group, non-inferiority study evaluating the safety and efficacy of isotretinoin-lidose in patients with severe recalcitrant nodular acne. J Drugs Dermatol 2014; 13: 665-70.
73. Dreno B, Thiboutot D, Gollnick H, et al,. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol 2014; 24: 330-4.
74. Zouboulis CC,. Is acne vulgaris a genuine inflammatory disease? Dermatology 2001; 203: 277-9.
75. Zouboulis CC, Eady A, Philpott M, et al,. What is the pathogenesis of acne? Exp Dermatol 2005; 14: 143-52.
76. 2 are active in sebaceous glands. J Mol Med 2006; 84: 75-87.
77. Zouboulis CC, Nestoris S, Adler YD, et al,. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol 2003; 139: 668-70.
78. Zouboulis CC,. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol 2009; 1: 188-92.
79. Zouboulis CC, Saborowski A, Boschnakow A,. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 2005; 210: 36-8.
80. Zouboulis CC, Seltmann H, Alestas T,. Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis. Exp Dermatol 2010; 19: 148-50.
81. Alesci S, Bornstein SR,. Neuroimmunoregulation of androgens in the adrenal gland and the skin. Horm Res 2000; 54: 281-6.
82. Goldstein JA, Comite H, Mescon H, Pochi PE,. Isotretinoin in the treatment of acne: histologic changes, sebum production, and clinical observations. Arch Dermatol 1982; 118: 555-8.
83. Hennes R, Mack A, Schell H, Vogt HJ,. 13-cis-retinoic acid in conglobate acne. A follow-up study of 14 trial centers. Arch Dermatol Res 1984; 276: 209-15.
84. Harms M, Masouye I, Radeff B,. The relapses of cystic acne after isotretinoin treatment are age-related: a long-term follow-up study. Dermatologica 1986; 172: 148-53.
85. Cunliffe WJ, Norris JF,. Isotretinoin-an explanation for its long-term benefit. Dermatologica 1987; 175 (Suppl. 1): 133-7.
86. Lehucher-Ceyrac D, Weber-Buisset MJ,. Isotretinoin and acne in practice: a prospective analysis of 188 cases over 9 years. Dermatology 1993; 186: 123-8.
87. Lehucher-Ceyrac D, de La Salmoniere P, Chastang C, Morel P,. Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 1999; 198: 278-83.
88. Shahidullah M, Tham SN, Goh CL,. Isotretinoin therapy in acne vulgaris: a 10-year retrospective study in Singapore. Int J Dermatol 1994; 33: 60-3.
89. Goulden V, Clark SM, McGeown C, Cunliffe WJ,. Treatment of acne with intermittent isotretinoin. Br J Dermatol 1997; 137: 106-8.
90. Rasi A, Behrangi E, Rohaninasab M, Nahad ZM,. Efficacy of fixed daily 20 mg of isotretinoin in moderate to severe scar prone acne. Adv Biomed Res 2014; 3: 103.